Payment overview · 2025
General Payments
$40.10
1 reported records · 1 companies
Healthcare provider profile · identity verified
Anupama Sharma, MD
Allopathic & Osteopathic Physicians|Internal Medicine · VICTORVILLE, CA · NPI 1851387948
Verified facts
What the public records show
CMS Open Payments records show Anupama Sharma, MD received $40.10 in general payments during 2025 across 1 reported records.
MERZ NORTH AMERICA, INC. accounted for 100.0% of that reported general-payment amount.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| MERZ NORTH AMERICA, INC. | Unresolved — no canonical attribution shown | $40.10 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $40.10 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 348 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 275 | 81 |
| Simvastatin | Simvastatin | 248 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 236 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 234 | 63 |
| Metformin Hcl | Metformin Hcl | 225 | 67 |
| Lisinopril | Lisinopril | 215 | 64 |
| Losartan Potassium | Losartan Potassium | 214 | 66 |
| Gabapentin | Gabapentin | 205 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 55 |
| Omeprazole | Omeprazole | 186 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 43 |
| Ozempic | Semaglutide | 115 | 22 |
| Atenolol | Atenolol | 112 | 33 |
| Alendronate Sodium | Alendronate Sodium | 102 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 100 | 32 |
| Baclofen | Baclofen | 99 | 44 |
| Eliquis | Apixaban | 93 | 18 |
| Potassium Chloride | Potassium Chloride | 91 | 27 |
| Furosemide | Furosemide | 90 | 34 |
| Januvia | Sitagliptin Phosphate | 77 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 26 |
| Carvedilol | Carvedilol | 71 | 20 |
| Sertraline Hcl | Sertraline Hcl | 70 | 24 |
| Trazodone Hcl | Trazodone Hcl | 64 | 22 |
| Meloxicam | Meloxicam | 62 | 17 |
| Glipizide | Glipizide | 61 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 18 |
| Montelukast Sodium | Montelukast Sodium | 52 | 19 |
| Celecoxib | Celecoxib | 51 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 13 |
| Allopurinol | Allopurinol | 49 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 14 |
| Trulicity | Dulaglutide | 47 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 16 |
| Benazepril Hcl | Benazepril Hcl | 43 | 11 |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Nifedipine Er | Nifedipine | 38 | 11 |
| Alprazolam | Alprazolam | 36 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Ezetimibe | Ezetimibe | 36 | 12 |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 17 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | 14 |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 14 |
| Finasteride | Finasteride | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Pentoxifylline | Pentoxifylline | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Toremifene Citrate | Toremifene Citrate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $40.10 · 1 records | MERZ NORTH AMERICA, INC. | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error